Symbols / NEOG
NEOG Chart
About
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and unintended substances in human food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides software systems that help testers analyze and store results; natural toxin tests; rapid sanitation tests; culture and prepared media products; filter tests for microbial analysis of water; sample collection products; and food safety analysis laboratory services. This segment sells its products to the milling and grain, meat and poultry, ready-to-eat, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. Its Animal Safety segment provides reagents and test kits for use in immunoassay production, forensic and animal toxicology, and life science research, as well as colorimetric and chemiluminescent substrates; veterinary instruments and disposables; animal care and other products, including digestive aids and nutritional supplements; rodent and insect control products, and disinfectants; and genomics services, such as DNA genotyping, sequencing, and trait analysis for livestock and companion animals. This segment sells its products to companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 2.09B |
| Enterprise Value | 2.76B | Income | -602.74M | Sales | 880.32M |
| Book/sh | 9.68 | Cash/sh | 0.67 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2974 | IPO | — |
| P/E | — | Forward P/E | 29.66 | PEG | — |
| P/S | 2.37 | P/B | 0.99 | P/C | — |
| EV/EBITDA | 30.54 | EV/Sales | 3.13 | Quick Ratio | 1.89 |
| Current Ratio | 3.91 | Debt/Eq | 37.78 | LT Debt/Eq | — |
| EPS (ttm) | -2.78 | EPS next Y | 0.32 | EPS Growth | — |
| Revenue Growth | -2.80% | Earnings | 2026-04-08 | ROA | -0.46% |
| ROE | -25.25% | ROIC | — | Gross Margin | 45.98% |
| Oper. Margin | -2.39% | Profit Margin | -68.47% | Shs Outstand | 217.53M |
| Shs Float | 216.36M | Short Float | 6.43% | Short Ratio | 3.22 |
| Short Interest | — | 52W High | 11.43 | 52W Low | 3.87 |
| Beta | 1.95 | Avg Volume | 3.70M | Volume | 81.72K |
| Target Price | $11.67 | Recom | Buy | Prev Close | $9.70 |
| Price | $9.59 | Change | -1.13% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.67
Mean price target
2. Current target
$9.59
Latest analyst target
3. DCF / Fair value
$-0.08
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.59
Low
$10.00
High
$13.00
Mean
$11.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-12 | reit | Piper Sandler | Neutral → Neutral | $10 |
| 2026-01-09 | main | Guggenheim | Buy → Buy | $12 |
| 2025-12-10 | up | CJS Securities | Market Perform → Market Outperform | $10 |
| 2025-10-16 | reit | Piper Sandler | Neutral → Neutral | $7 |
| 2025-09-29 | init | CJS Securities | — → Market Perform | $10 |
| 2025-07-29 | down | William Blair | Outperform → Market Perform | — |
| 2025-06-30 | main | Guggenheim | Buy → Buy | $10 |
| 2025-04-22 | main | Piper Sandler | Neutral → Neutral | $5 |
| 2025-04-14 | main | Piper Sandler | Neutral → Neutral | $7 |
| 2025-04-10 | main | Guggenheim | Buy → Buy | $13 |
| 2025-01-21 | reit | Piper Sandler | Neutral → Neutral | $13 |
| 2024-12-19 | init | Guggenheim | — → Buy | $15 |
| 2024-08-06 | main | Piper Sandler | Neutral → Neutral | $18 |
| 2024-04-15 | main | Piper Sandler | Neutral → Neutral | $17 |
| 2024-01-18 | main | Piper Sandler | Neutral → Neutral | $19 |
| 2023-10-16 | main | Piper Sandler | Neutral → Neutral | $18 |
| 2023-08-14 | main | Wells Fargo | Overweight → Overweight | $28 |
| 2023-06-16 | init | Wells Fargo | — → Overweight | $22 |
| 2022-12-15 | main | Piper Sandler | — → Neutral | $17 |
| 2022-11-22 | up | William Blair | Market Perform → Outperform | — |
- Is Neogen (NEOG) Pricing Make Sense After Mixed Share Performance This Year - simplywall.st ue, 10 Mar 2026 05
- Neogen Stock (-9.3%): Genomics Divestiture Weighed Negatively By Market - Trefis Sat, 07 Mar 2026 11
- JPMorgan Chase & Co. Purchases 278,886 Shares of Neogen Corporation $NEOG - MarketBeat Sat, 07 Mar 2026 09
- Responsive Playbooks and the NEOG Inflection - Stock Traders Daily Mon, 09 Mar 2026 11
- Nassif Mikheal, CEO of Neogen, buys $251 in Neog stock - Investing.com ue, 17 Feb 2026 08
- Why Is Neogen (NEOG) Stock Rocketing Higher Today - Yahoo Finance hu, 08 Jan 2026 08
- Is it Worth Retaining NEOG Stock in Your Portfolio for Now? - Zacks Investment Research Wed, 10 Dec 2025 08
- Neogen sheds $90M genomics unit in $160M Zoetis deal to cut debt - Stock Titan Mon, 02 Mar 2026 12
- Clarkston Capital Partners LLC Has $66.77 Million Position in Neogen Corporation $NEOG - MarketBeat Mon, 09 Mar 2026 09
- Why Neogen (NEOG) Stock Is Trading Up Today - Yahoo Finance hu, 09 Oct 2025 07
- Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 46% Jump Looks Justified - simplywall.st Mon, 02 Feb 2026 08
- Teton Advisors LLC Makes New Investment in Neogen Corporation $NEOG - MarketBeat Sat, 07 Mar 2026 13
- Is It Time To Reassess Neogen (NEOG) After Its Strong Year To Date Rally? - Yahoo Finance Sat, 28 Feb 2026 08
- Assessing Neogen (NEOG) Valuation After A Sharp Short Term Share Price Rebound - simplywall.st Sat, 28 Feb 2026 08
- Vanguard Group Inc. Acquires 385,885 Shares of Neogen Corporation $NEOG - MarketBeat Wed, 04 Mar 2026 13
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 23 | 252 | — | Purchase at price 10.94 per share. | NASSIF MIKHEAL | Chief Executive Officer | — | 2026-02-17 00:00:00 | I |
| 1 | 49 | 486 | — | Purchase at price 9.86 - 10.00 per share. | NASSIF MIKHEAL | Chief Executive Officer | — | 2026-02-02 00:00:00 | I |
| 2 | 137 | 1279 | — | Purchase at price 9.33 per share. | NASSIF MIKHEAL | Chief Executive Officer | — | 2026-01-16 00:00:00 | I |
| 3 | 50813 | 375000 | — | Stock Award(Grant) at price 7.38 per share. | RANALLI TAMARA A | Officer | — | 2026-01-07 00:00:00 | D |
| 4 | 101626 | 750000 | — | Stock Award(Grant) at price 7.38 per share. | RANALLI TAMARA A | Officer | — | 2026-01-07 00:00:00 | D |
| 5 | 12912 | 77214 | — | Conversion of Exercise of derivative security at price 5.98 per share. | NAEMURA DAVID HARTMAN | Former | — | 2025-12-01 00:00:00 | D |
| 6 | 178855 | 1124998 | — | Stock Award(Grant) at price 6.29 per share. | RIGGSBEE RICHARD BRYAN | Chief Financial Officer | — | 2025-11-03 00:00:00 | D |
| 7 | 177 | 1106 | — | Purchase at price 6.25 per share. | NASSIF MIKHEAL | Chief Executive Officer | — | 2025-11-03 00:00:00 | I |
| 8 | 1777 | 11000 | — | Conversion of Exercise of derivative security at price 6.19 per share. | TOBIN JAMES P | Director | — | 2025-10-27 00:00:00 | D |
| 9 | 3553 | 21567 | — | Conversion of Exercise of derivative security at price 6.07 per share. | BOEHM WILLIAM T | Director | — | 2025-10-27 00:00:00 | D |
Financials
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -38.39M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.04 | 0.34 | 0.21 | 0.20 |
| NormalizedEBITDA | 123.50M | 180.32M | 124.39M | 84.41M |
| TotalUnusualItems | -1.06B | 0.00 | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | -1.06B | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -1.09B | -9.42M | -22.87M | 48.31M |
| ReconciledDepreciation | 125.67M | 121.23M | 90.47M | 24.13M |
| ReconciledCostOfRevenue | 473.29M | 460.32M | 416.49M | 284.15M |
| EBITDA | -935.82M | 180.32M | 124.39M | 84.41M |
| EBIT | -1.06B | 59.09M | 33.92M | 60.28M |
| NetInterestIncome | -68.51M | -67.03M | -52.80M | 1.27M |
| InterestExpense | 71.62M | 73.39M | 55.96M | 72.00K |
| InterestIncome | 3.11M | 6.36M | 3.17M | 1.34M |
| NormalizedIncome | -71.11M | -9.42M | -22.87M | 48.31M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -1.09B | -9.42M | -22.87M | 48.31M |
| TotalExpenses | 896.34M | 865.56M | 784.93M | 468.54M |
| TotalOperatingIncomeAsReported | -1.06B | 58.66M | 37.52M | 58.62M |
| DilutedAverageShares | 217.04M | 216.61M | 216.25M | 108.02M |
| BasicAverageShares | 217.04M | 216.61M | 216.25M | 107.80M |
| DilutedEPS | -5.03 | -0.04 | -0.12 | 0.45 |
| BasicEPS | -5.03 | -0.04 | -0.11 | 0.45 |
| DilutedNIAvailtoComStockholders | -1.09B | -9.42M | -22.87M | 48.31M |
| NetIncomeCommonStockholders | -1.09B | -9.42M | -22.87M | 48.31M |
| NetIncome | -1.09B | -9.42M | -22.87M | 48.31M |
| NetIncomeIncludingNoncontrollingInterests | -1.09B | -9.42M | -22.87M | 48.31M |
| NetIncomeContinuousOperations | -1.09B | -9.42M | -22.87M | 48.31M |
| TaxProvision | -41.07M | -4.88M | 828.00K | 11.90M |
| PretaxIncome | -1.13B | -14.30M | -22.04M | 60.21M |
| OtherIncomeExpense | -3.60M | -5.94M | -6.76M | 322.00K |
| OtherNonOperatingIncomeExpenses | 1.06B | -5.94M | -6.76M | 322.00K |
| SpecialIncomeCharges | -1.06B | 0.00 | 0.00 | |
| ImpairmentOfCapitalAssets | 1.06B | 0.00 | 0.00 | |
| NetNonOperatingInterestIncomeExpense | -68.51M | -67.03M | -52.80M | 1.27M |
| InterestExpenseNonOperating | 71.62M | 73.39M | 55.96M | 72.00K |
| InterestIncomeNonOperating | 3.11M | 6.36M | 3.17M | 1.34M |
| OperatingIncome | -1.68M | 58.66M | 37.52M | 58.62M |
| OperatingExpense | 423.05M | 405.24M | 368.44M | 184.40M |
| ResearchAndDevelopment | 21.09M | 22.48M | 26.04M | 17.05M |
| SellingGeneralAndAdministration | 401.96M | 382.76M | 342.40M | 167.35M |
| SellingAndMarketingExpense | 183.80M | 182.87M | 141.22M | 84.60M |
| GeneralAndAdministrativeExpense | 218.17M | 199.89M | 201.18M | 82.74M |
| OtherGandA | 218.17M | 199.89M | 201.18M | 82.74M |
| GrossProfit | 421.38M | 463.90M | 405.95M | 243.01M |
| CostOfRevenue | 473.29M | 460.32M | 416.49M | 284.15M |
| TotalRevenue | 894.66M | 924.22M | 822.45M | 527.16M |
| OperatingRevenue | 894.66M | 924.22M | 822.45M | 527.16M |
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 217.04M | 216.61M | 216.25M | 107.80M |
| ShareIssued | 217.04M | 216.61M | 216.25M | 107.80M |
| NetDebt | 765.11M | 720.23M | 722.20M | |
| TotalDebt | 894.11M | 890.84M | 885.44M | |
| TangibleBookValue | -404.13M | -503.14M | -608.38M | 637.17M |
| InvestedCapital | 2.97B | 4.03B | 4.02B | 887.37M |
| WorkingCapital | 402.93M | 434.91M | 440.46M | 548.95M |
| NetTangibleAssets | -404.13M | -503.14M | -608.38M | 637.17M |
| CapitalLeaseObligations | 0.00 | 0.00 | ||
| CommonStockEquity | 2.07B | 3.14B | 3.13B | 887.37M |
| TotalCapitalization | 2.95B | 4.03B | 4.02B | 887.37M |
| TotalEquityGrossMinorityInterest | 2.07B | 3.14B | 3.13B | 887.37M |
| StockholdersEquity | 2.07B | 3.14B | 3.13B | 887.37M |
| GainsLossesNotAffectingRetainedEarnings | -28.90M | -30.02M | -33.25M | -27.77M |
| OtherEquityAdjustments | -28.90M | -30.02M | -33.25M | -27.77M |
| RetainedEarnings | -536.42M | 555.62M | 565.04M | 587.91M |
| AdditionalPaidInCapital | 2.60B | 2.58B | 2.57B | 309.98M |
| CapitalStock | 34.73M | 34.66M | 34.60M | 17.25M |
| CommonStock | 34.73M | 34.66M | 34.60M | 17.25M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.37B | 1.40B | 1.42B | 105.56M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.20B | 1.25B | 1.27B | 27.71M |
| OtherNonCurrentLiabilities | 42.85M | 35.26M | 35.88M | 10.70M |
| NonCurrentDeferredLiabilities | 280.91M | 326.72M | 353.43M | 17.01M |
| NonCurrentDeferredTaxesLiabilities | 280.91M | 326.72M | 353.43M | 17.01M |
| LongTermDebtAndCapitalLeaseObligation | 874.81M | 888.39M | 885.44M | |
| LongTermCapitalLeaseObligation | 0.00 | |||
| LongTermDebt | 874.81M | 888.39M | 885.44M | |
| CurrentLiabilities | 174.01M | 154.32M | 145.47M | 77.84M |
| OtherCurrentLiabilities | 38.74M | 22.80M | 20.93M | |
| CurrentDeferredLiabilities | 5.56M | 4.63M | 4.62M | 5.46M |
| CurrentDeferredRevenue | 5.56M | 4.63M | 4.62M | 5.46M |
| CurrentDebtAndCapitalLeaseObligation | 19.30M | 2.45M | ||
| CurrentCapitalLeaseObligation | 2.45M | 0.00 | ||
| CurrentDebt | 19.30M | 2.45M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 14.13M | 19.95M | 25.15M | 11.12M |
| PayablesAndAccruedExpenses | 96.28M | 104.50M | 94.77M | 61.26M |
| CurrentAccruedExpenses | 11.08M | 10.98M | 11.15M | 24.52M |
| InterestPayable | 11.08M | 10.98M | 11.15M | 0.00 |
| Payables | 85.20M | 93.51M | 83.62M | 36.74M |
| TotalTaxPayable | 5.60M | 10.45M | 6.95M | 2.13M |
| IncomeTaxPayable | 5.60M | 10.45M | 6.95M | 2.13M |
| AccountsPayable | 79.61M | 83.06M | 76.67M | 34.61M |
| TotalAssets | 3.44B | 4.55B | 4.55B | 992.93M |
| TotalNonCurrentAssets | 2.87B | 3.96B | 3.97B | 366.13M |
| OtherNonCurrentAssets | 35.23M | 20.43M | 15.22M | 2.16M |
| GoodwillAndOtherIntangibleAssets | 2.48B | 3.65B | 3.74B | 250.21M |
| OtherIntangibleAssets | 1.41B | 1.51B | 1.61B | 107.50M |
| Goodwill | 1.06B | 2.14B | 2.14B | 142.70M |
| NetPPE | 356.28M | 291.89M | 210.68M | 113.77M |
| AccumulatedDepreciation | -155.43M | -140.29M | -120.12M | -104.88M |
| GrossPPE | 511.71M | 432.18M | 330.80M | 218.64M |
| ConstructionInProgress | 186.24M | 113.97M | 52.24M | 5.97M |
| OtherProperties | 17.15M | 14.79M | 11.93M | 3.18M |
| MachineryFurnitureEquipment | 188.78M | 184.63M | 159.63M | 120.49M |
| BuildingsAndImprovements | 108.72M | 108.30M | 96.79M | 79.51M |
| LandAndImprovements | 10.82M | 10.50M | 10.21M | 9.48M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 576.94M | 589.23M | 585.93M | 626.80M |
| OtherCurrentAssets | 53.29M | 56.02M | 53.30M | 23.76M |
| AssetsHeldForSaleCurrent | 50.40M | 0.00 | ||
| PrepaidAssets | 23.76M | 17.84M | ||
| Inventory | 190.86M | 189.27M | 133.81M | 122.31M |
| InventoriesAdjustmentsAllowances | -16.48M | -12.36M | -6.27M | |
| FinishedGoods | 130.42M | 111.84M | 68.10M | 57.26M |
| WorkInProcess | 11.23M | 10.99M | 5.37M | 6.39M |
| RawMaterials | 65.69M | 78.80M | 66.62M | 58.67M |
| Receivables | 153.38M | 173.00M | 153.25M | 99.67M |
| AccountsReceivable | 153.38M | 173.00M | 153.25M | 99.67M |
| AllowanceForDoubtfulAccountsReceivable | -5.40M | -4.14M | -2.83M | -1.65M |
| GrossAccountsReceivable | 158.78M | 177.15M | 156.08M | 101.32M |
| CashCashEquivalentsAndShortTermInvestments | 129.00M | 170.94M | 245.57M | 381.05M |
| OtherShortTermInvestments | 0.00 | 325.00K | 82.33M | 336.58M |
| CashAndCashEquivalents | 129.00M | 170.61M | 163.24M | 44.47M |
| Line Item | 2025-05-31 | 2024-05-31 | 2023-05-31 | 2022-05-31 |
|---|---|---|---|---|
| FreeCashFlow | -46.35M | -76.16M | -24.73M | 43.61M |
| RepurchaseOfCapitalStock | 0.00 | |||
| RepaymentOfDebt | -550.32M | -420.00K | -100.00M | 0.00 |
| IssuanceOfDebt | 550.00M | 0.00 | 0.00 | |
| CapitalExpenditure | -104.59M | -111.42M | -65.76M | -24.43M |
| InterestPaidSupplementalData | 68.14M | 73.17M | 42.62M | 72.00K |
| IncomeTaxPaidSupplementalData | 26.54M | 22.30M | 15.47M | 17.24M |
| EndCashPosition | 129.00M | 170.61M | 163.24M | 44.47M |
| BeginningCashPosition | 170.61M | 163.24M | 44.47M | 75.60M |
| EffectOfExchangeRateChanges | 942.00K | -502.00K | -5.22M | -8.75M |
| ChangesInCash | -42.55M | 7.87M | 123.99M | -22.38M |
| FinancingCashFlow | -1.60M | 1.92M | -118.08M | 6.81M |
| CashFlowFromContinuingFinancingActivities | -1.60M | 1.92M | -118.08M | 6.81M |
| NetOtherFinancingCharges | -3.52M | -118.00K | -19.28M | -1.12M |
| ProceedsFromStockOptionExercised | 2.24M | 2.46M | 1.20M | 7.93M |
| NetCommonStockIssuance | 0.00 | |||
| CommonStockPayments | 0.00 | |||
| NetIssuancePaymentsOfDebt | -321.00K | -420.00K | -100.00M | 0.00 |
| NetLongTermDebtIssuance | -321.00K | -420.00K | -100.00M | 0.00 |
| LongTermDebtPayments | -550.32M | -420.00K | -100.00M | 0.00 |
| LongTermDebtIssuance | 550.00M | 0.00 | 0.00 | |
| InvestingCashFlow | -99.19M | -29.31M | 201.04M | -97.23M |
| CashFlowFromContinuingInvestingActivities | -99.19M | -29.31M | 201.04M | -97.23M |
| NetInvestmentPurchaseAndSale | 325.00K | 82.00M | 254.25M | -34.05M |
| SaleOfInvestment | 325.00K | 82.00M | 266.77M | 381.84M |
| PurchaseOfInvestment | 0.00 | 0.00 | -12.52M | -415.89M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | 11.72M | -38.74M |
| SaleOfBusiness | 0.00 | 0.00 | 11.72M | |
| PurchaseOfBusiness | -38.74M | -50.77M | ||
| NetPPEPurchaseAndSale | -99.52M | -111.31M | -64.93M | -24.43M |
| SaleOfPPE | 5.08M | 108.00K | 826.00K | 0.00 |
| PurchaseOfPPE | -104.59M | -111.42M | -65.76M | -24.43M |
| OperatingCashFlow | 58.24M | 35.26M | 41.03M | 68.04M |
| CashFlowFromContinuingOperatingActivities | 58.24M | 35.26M | 41.03M | 68.04M |
| ChangeInWorkingCapital | -5.93M | -72.68M | -24.20M | -4.42M |
| ChangeInOtherWorkingCapital | 360.00K | -21.33M | 154.00K | 8.27M |
| ChangeInPayablesAndAccruedExpense | -309.00K | 13.59M | 22.69M | 20.24M |
| ChangeInAccruedExpense | 93.00K | -164.00K | 4.05M | 0.00 |
| ChangeInInterestPayable | 93.00K | -164.00K | 4.05M | 0.00 |
| ChangeInPayable | -402.00K | 13.75M | 18.64M | 20.24M |
| ChangeInAccountPayable | -402.00K | 13.75M | 18.64M | 20.24M |
| ChangeInPrepaidAssets | -1.50M | 11.11M | -3.12M | -4.05M |
| ChangeInInventory | -16.12M | -55.95M | 9.96M | -21.07M |
| ChangeInReceivables | 11.64M | -20.10M | -53.88M | -7.80M |
| ChangesInAccountReceivables | 11.64M | -20.10M | -53.88M | -7.80M |
| OtherNonCashItems | 380.00K | 8.72M | 7.16M | -2.44M |
| StockBasedCompensation | 17.29M | 13.77M | 10.18M | 7.15M |
| AssetImpairmentCharge | 1.07B | 0.00 | 0.00 | 0.00 |
| DeferredTax | -57.78M | -27.42M | -19.23M | -4.70M |
| DeferredIncomeTax | -57.78M | -27.42M | -19.23M | -4.70M |
| DepreciationAmortizationDepletion | 125.67M | 121.23M | 90.47M | 24.13M |
| DepreciationAndAmortization | 125.67M | 121.23M | 90.47M | 24.13M |
| Depreciation | 125.67M | 121.23M | 90.47M | 24.13M |
| OperatingGainsLosses | 1.91M | 1.07M | -486.00K | |
| GainLossOnSaleOfPPE | -25.00K | 1.07M | -486.00K | 0.00 |
| NetIncomeFromContinuingOperations | -1.09B | -9.42M | -22.87M | 48.31M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NEOG
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|